Overdiagnosis of bone fragility in the quest to prevent hip fracture
暂无分享,去创建一个
G. Collins | K. Michaëlsson | H. Sievänen | T. Järvinen | J. Jokihaara | B. Mintzes | V. Musini | T. Perry | J. Gorricho | J. Erviti | J. Wright
[1] P. Kannus,et al. Osteoporosis and vertebral fractures: a newly discovered epidemic or just an example of overdiagnosis and disease mongering? , 2017 .
[2] S. Perera,et al. Efficacy and safety of single-dose zoledronic acid for osteoporosis in frail elderly women: a randomized clinical trial. , 2015, JAMA internal medicine.
[3] I. Redlund‐Johnell,et al. Low clinical relevance of a prevalent vertebral fracture in elderly men--the MrOs Sweden study. , 2015, The spine journal : official journal of the North American Spine Society.
[4] K. Michaëlsson,et al. Risk of atypical femoral fracture during and after bisphosphonate use , 2015, Acta orthopaedica.
[5] J. Cauley,et al. Secular Trends in Hip Fractures Worldwide: Opposing Trends East Versus West , 2014, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[6] I. Reid,et al. Skeletal and nonskeletal effects of vitamin D: is vitamin D a tonic for bone and other tissues? , 2014, Osteoporosis International.
[7] I. Reid,et al. The effect of vitamin D supplementation on skeletal, vascular, or cancer outcomes: a trial sequential meta-analysis. , 2014, The lancet. Diabetes & endocrinology.
[8] Gary S Collins,et al. Conflicts at the heart of the FRAX tool , 2014, Canadian Medical Association Journal.
[9] I. Reid. Should We Prescribe Calcium Supplements For Osteoporosis Prevention? , 2014, Journal of bone metabolism.
[10] Per Aspenberg,et al. Denosumab and atypical femoral fractures , 2014, Acta orthopaedica.
[11] Marie-Aline Charles,et al. The effect of fall prevention exercise programmes on fall induced injuries in community dwelling older adults: systematic review and meta-analysis of randomised controlled trials , 2013, British Journal of Sports Medicine.
[12] C. Cooper,et al. Osteoporosis in the European Union: medical management, epidemiology and economic burden , 2013, Archives of Osteoporosis.
[13] J. Kanis,et al. Diagnosis and management of osteoporosis in postmenopausal women and older men in the UK: National Osteoporosis Guideline Group (NOGG) update 2013. , 2013, Maturitas.
[14] P. Kannus,et al. Continuous decline in incidence of hip fracture: nationwide statistics from Finland between 1970 and 2010 , 2013, Osteoporosis International.
[15] Gary S Collins,et al. Fracture Risk Assessment: State of the Art, Methodologically Unsound, or Poorly Reported? , 2012, Current Osteoporosis Reports.
[16] Marcea Whitaker,et al. Bisphosphonates for osteoporosis--where do we go from here? , 2012, The New England journal of medicine.
[17] I. Reid. Bisphosphonates in the treatment of osteoporosis: a review of their contribution and controversies , 2011, Skeletal Radiology.
[18] C. Cooper,et al. Clinicians need to treat underlying osteoporosis , 2011, BMJ : British Medical Journal.
[19] Thomas D Brown,et al. Atypical Subtrochanteric and Diaphyseal Femoral Fractures: Second Report of a Task Force of the American Society for Bone and Mineral Research , 2011, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[20] C. Cooper,et al. Interpretation and use of FRAX in clinical practice , 2011, Osteoporosis International.
[21] P. Kannus,et al. The true cost of pharmacological disease prevention , 2011, BMJ : British Medical Journal.
[22] A. Avenell,et al. Calcium supplements with or without vitamin D and risk of cardiovascular events: reanalysis of the Women’s Health Initiative limited access dataset and meta-analysis , 2011, BMJ : British Medical Journal.
[23] R. Eastell,et al. Cumulative alendronate dose and the long-term absolute risk of subtrochanteric and diaphyseal femur fractures: a register-based national cohort analysis. , 2010, The Journal of clinical endocrinology and metabolism.
[24] S. Boonen,et al. Efficacy and Safety of a Once‐Yearly Intravenous Zoledronic Acid 5 mg for Fracture Prevention in Elderly Postmenopausal Women with Osteoporosis Aged 75 and Older , 2010, Journal of the American Geriatrics Society.
[25] A. LaCroix,et al. Patient level pooled analysis of 68 500 patients from seven major vitamin D fracture trials in US and Europe , 2010, BMJ : British Medical Journal.
[26] Claus Christiansen,et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. , 2009, The New England journal of medicine.
[27] S. Cummings,et al. Estimates of the Proportion of Older White Women Who Would Be Recommended for Pharmacologic Treatment by the New U.S. National Osteoporosis Foundation Guidelines , 2009, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[28] J. Kanis,et al. Case finding for the management of osteoporosis with FRAX®—assessment and intervention thresholds for the UK , 2008, Osteoporosis International.
[29] L. Melton,et al. Cost-effective osteoporosis treatment thresholds: the United States perspective , 2008, Osteoporosis International.
[30] G. Guyatt,et al. Drugs for pre-osteoporosis: prevention or disease mongering? , 2008, BMJ : British Medical Journal.
[31] Ari Heinonen,et al. Shifting the focus in fracture prevention from osteoporosis to falls , 2008, BMJ : British Medical Journal.
[32] Lisa M. Schwartz,et al. Implications of expanding disease definitions: the case of osteoporosis. , 2007, Health affairs.
[33] S. Boonen,et al. Zoledronic acid and clinical fractures and mortality after hip fracture. , 2007, The New England journal of medicine.
[34] K. Michaëlsson,et al. Leisure Physical Activity and the Risk of Fracture in Men , 2007, PLoS medicine.
[35] Pekka Kannus,et al. Bone Quality: An Empty Term , 2007, PLoS medicine.
[36] J. Pasco,et al. Half the burden of fragility fractures in the community occur in women without osteoporosis. When is fracture prevention cost-effective? , 2006, Bone.
[37] K. Michaëlsson,et al. Smoking and the Risk of Fracture in Older Men , 2005, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[38] A. Silman,et al. Predictive Value of BMD for Hip and Other Fractures , 2005, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[39] J. Reginster,et al. Strontium ranelate reduces the risk of nonvertebral fractures in postmenopausal women with osteoporosis: Treatment of Peripheral Osteoporosis (TROPOS) study. , 2005, The Journal of clinical endocrinology and metabolism.
[40] H. Kroger,et al. Smoking and fracture risk: a meta-analysis , 2005, Osteoporosis International.
[41] S. Cummings,et al. BMD at Multiple Sites and Risk of Fracture of Multiple Types: Long‐Term Results From the Study of Osteoporotic Fractures , 2003, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[42] M. Tinetti. Clinical practice. Preventing falls in elderly persons. , 2003, The New England journal of medicine.
[43] W. Willett,et al. Walking and leisure-time activity and risk of hip fracture in postmenopausal women. , 2002, JAMA.
[44] P. Kannus,et al. Why Is the Age‐Standardized Incidence of Low‐Trauma Fractures Rising in Many Elderly Populations? , 2002, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[45] P Geusens,et al. Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group. , 2001, The New England journal of medicine.
[46] O Johnell,et al. Risk of hip fracture according to the World Health Organization criteria for osteopenia and osteoporosis. , 2000, Bone.
[47] Christianna S. Williams,et al. Falls, injuries due to falls, and the risk of admission to a nursing home. , 1997, The New England journal of medicine.
[48] M. Hochberg. Bisphosphonates in the treatment of osteoporosis. , 1997, Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases.
[49] O Johnell,et al. Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures. , 1996, BMJ.
[50] J. Kanis,et al. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis: Synopsis of a WHO report , 1994, Osteoporosis International.
[51] S. Cummings,et al. Results of bone densitometry affect women's decisions about taking measures to prevent fractures. , 1992, Annals of internal medicine.
[52] N J Wald,et al. Strategies for prevention of osteoporosis and hip fracture. , 1991, BMJ.
[53] O. Törring,et al. Osteonecrosis of the jaw in Sweden associated with the oral use of bisphosphonate. , 2014, Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons.
[54] J. Gilliland,et al. Comparison of hip fracture and osteoporosis medication prescription rates across Canadian provinces , 2013, Osteoporosis International.
[55] M. Swiontkowski. Cumulative Alendronate Dose and the Long-Term Absolute Risk of Subtrochanteric and Diaphyseal Femur Fractures: A Register-Based National Cohort Analysis , 2011 .
[56] G. Oster,et al. Effectiveness of bisphosphonate therapy in a community setting. , 2009, Bone.
[57] O. Johnell,et al. The Burden of Osteoporotic Fractures: A Method for Setting Intervention Thresholds , 2001, Osteoporosis International.
[58] N. Pedersen,et al. American Journal of Epidemiology Original Contribution Simply Ask Them about Their Balance—future Fracture Risk in a Nationwide Cohort Study of Twins , 2022 .